7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment ... #ActiveTB #LatentTB
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment ... #ActiveTB #LatentTB
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Mycobacterium tuberculosis ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Pneumocystis pneumonia (PCP ... Mycobacterium tuberculosis ... #OIs #HIVAIDS #IDSA ... #management #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... or been newly diagnosed ... , and sexually active ... Prevention #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... or latent TB ... and molecular diagnostic ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... Antiviral agents with activity ... KaposiSarcoma #Castlemans #IDSA ... Prevention #Treatment #management ... infections #HIVAIDS #pharmacology